ECNP 2021 | The Equity in Neuroscience and Alzheimer’s Clinical Trials (ENACT) Act

Charles Wilcox, PhD, MPA, MBA, Praxis Research Consulting, Newport Beach, CA, discusses the Equity in Neuroscience and Alzheimer’s Clinical Trials (ENACT) Act, American legislation introduced to increase clinical trial participation among underrepresented populations. Alzheimer’s disease disproportionately affect Black and Hispanic Americans compared to Whites, but these populations are underrepresented at every stage of the research process. Supported by The Alzheimer’s Association and the Alzheimer’s Impact Movement (AIM), the ENACT act aims to expand education and outreach to underrepresented populations, encourage diversity amongst clinical trial staff, and reduce participation burden. This interview took place at the European College of Neuropsychopharmacology congress 2021.